TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28323627
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (100 mL of 10% normal saline injection, 3 times a day)
Study: 26040478
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 mcg administered intravaginally 10 and 4 hours before IUC insertion attempt.
Study: 26040478
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravaginally 10 and 4 hours before IUC insertion attempt.
Study: 26040478
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 mcg administered intravaginally.
Study: 26040478
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravaginally.
Study: 22035998
Drug: Bupropion plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion plus functional analytic psychotherapy (FAP) and acceptance and commitment therapy (ACT)
Study: 19796802
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Gabapentin + Nortriptyline)
Study: 19796802
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment vs Gabapentin
Study: 19796802
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment vs Nortriptyline
Study: 12752353
Drug: Pellets (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pellets (500 mg of mesalazine and 2 mg of 152Sm2O3)
Study: 12752353
Drug: Tablets (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets (500 mg of mesalazine and 2 mg of 152Sm2O3)
Study: 11078989
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat load (OFLT) in obese subjects
Study: 11078989
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat load (OFLT) in healthy controls
Study: 11078989
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat load (OFLT) at 0700 h (diurnal test)
Study: 11078989
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat load (OFLT) at 2200 h (nocturnal test)
Study: 11078989
Drug: Baseline insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline insulin concentrations in obese subjects
Study: 11078989
Drug: Baseline insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline insulin concentrations in healthy controls
Study: 8791965
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg twice daily
Study: 1637562
Drug: Cream preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream preparations of triamcinolone acetonide and clobetasol propionate
Study: 1637562
Drug: Ointment preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment preparations of triamcinolone acetonide and clobetasol propionate
Study: 8008680
Drug: Acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400 mg daily)
Study: 29696061
Drug: Fennel vaginal
Normalized name: Fennel
DrugBank: Fennel (DB15615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fennel vaginal cream (5 grams) every night for 8 weeks
Study: 29696061
Drug: Fennel vaginal
Normalized name: Fennel
DrugBank: Fennel (DB15615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fennel vaginal cream
Study: 22710397
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate (34 g administered at 8 p.m. the night before the examination)
Study: 22710397
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation (no laxative administered)
Study: 17204156
Drug: Alcohol and
Normalized name: Polyvinyl alcohol and povidone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol and drug abuse and dependence (AAD/DAD) assessment using standardized procedures and structured interviews.
Study: 17204156
Drug: Regular screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular screening and treatment programs for AAD/DAD in prison.
Study: 7981578
Drug: Growth hormone-releasing
Normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Growth hormone-releasing hormone (GHRH; 100 micrograms)
Study: 2493400
Drug: Buserelin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (0.2 mg SC or 1.2 mg IN per day)
Study: 1105370
Drug: Pyritinol-HCl 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyritinol-HCl 300 mg/24 hr
Study: 26898264
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug therapy (Control)
Study: 24550190
Drug: AG (1
Normalized name: MGlcDAG (1->2) glucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG (1 µg/kg/h)
Study: 24550190
Drug: UAG (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: UAG (4 µg/kg/h)
Study: 23061628
Drug: Infliximab (5mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5mg/kg in a single intravenous infusion)
Study: 9773697
Drug: Intrathecal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal sufentanil 2, 5, or 10 microg (2 mL volume) and epidural saline (10 mL)
Study: 9773697
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine 5, 12.5, or 25 mg and intrathecal saline (2 mL volume)
Study: 9773697
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intrathecal sufentanil (1, 2.5, and 5 microg) plus epidural bupivacaine (2.5, 6.25, or 12.5 mg)
Study: 7828395
Drug: Potassium supplementation
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium supplementation (15 ml of potassium chloride with 0.9 mmol K per ml, three times a day) in group 2 (72 patients on diuretics)
Study: 7828395
Drug: 2-day preparation
Normalized name: Caviar Preparation
DrugBank: Caviar, unspecified (DB14241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-day preparation of 15 g magnesium sulphate and 10 mg bisacodyl twice daily in group 1 (55 patients on diuretics without potassium supplements)
Study: 7828395
Drug: 2-day preparation
Normalized name: Caviar Preparation
DrugBank: Caviar, unspecified (DB14241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-day preparation of 15 g magnesium sulphate and 10 mg bisacodyl twice daily in group 3 (97 patients)
Study: 7828395
Drug: 1-day preparation
Normalized name: Caviar Preparation
DrugBank: Caviar, unspecified (DB14241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day preparation of 2.4 mg sennoside per kg in group 4 (96 patients)
Study: 3338014
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with chlorambucil for 2 years
Study: 2149806
Drug: Gestodene preparation
Normalized name: gestodene
DrugBank: Gestodene (DB06730)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestodene preparation
Study: 2149806
Drug: Desogestrel preparation
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desogestrel preparation
Study: 31651350
Drug: 8.25 mg
Normalized name: leucine 8.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.25 mg dexamethasone intravenously after 8 hours of hypoxia with an FiO2 of 12%
Study: 18762944
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg daily plus calcium (1,000 mg) and vitamin D (800 IU)
Study: 18762944
Drug: Control (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (daily alfacalcidol (1 microg) plus calcium (500 mg) for those with prevalent vertebral fractures; daily vitamin D (800 IU) plus calcium (1,200 mg) for those without previous vertebral fractures)
Study: 17786099
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg controlled-release doxycycline
Study: 9744511
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cisplatin and vinblastine followed by surgery
Study: 9744511
Drug: Combined-modality treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality treatment (chemotherapy and surgery)
Study: 27250881
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin (35 mg/m2, 6 cycles)
Study: 27250881
Drug: 3 weekly
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 weekly cisplatin (100 mg/m2, 3 cycles)
Study: 19948879
Drug: Low-dose deferoxamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose deferoxamine (2.5 mg/kg/week)
Study: 19948879
Drug: Standard-dose deferoxamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose deferoxamine (5 mg/kg/week)
Study: 18608737
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg for 3 consecutive days, administered in three monthly pulses
Study: 15950634
Drug: TNF‐alpha plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐alpha plus infliximab (400 microg/mL)
Study: 10582984
Drug: IV/IA r-TPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV/IA r-TPA therapy
Study: 10582984
Drug: Placebo/IA therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/IA therapy
Study: 6140702
Drug: Withdrawal from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal from long-term benzodiazepine treatment
Study: 29845639
Drug: Benzocaine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine at 60, 85, 110, 135, and 160 mg/L
Study: 29845639
Drug: Eugenol at
Normalized name: Eugenol
DrugBank: Eugenol (DB09086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eugenol at 40, 80, 120, 160, and 200 mg/L
Study: 29845639
Drug: Menthol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menthol at 50, 75, 150, 200, and 250 mg/L
Study: 21395142
Drug: Intravenous amiodarone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone, 6 mg/kg/day
Study: 21395142
Drug: Oral propafenone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propafenone, 6.6 mg/kg/day
Study: 10354124
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous heparin infusion
Study: 1702569
Drug: Amiksin (0.125-0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiksin (0.125-0.25 g orally)
Study: 1702569
Drug: Amiksin (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiksin (1-2 tablets at least 2 days apart)
Study: 7460760
Drug: Methadone/methadyl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone/methadyl acetate treatment
Study: 22720766
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed fluoxetine treatment (once-weekly for 24 weeks, then self-administered for 12 weeks)
Study: 19885996
Drug: Cort80 (6.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cort80 (6.3 mg/hr/70 kg)
Study: 19885996
Drug: Cort160 (12.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cort160 (12.6 mg/hr/70 kg)
Study: 17760727
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication treatment with amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d., and omeprazole 20 mg b.i.d. for 14 days in patients with positive (13)C-UBT.
Study: 17760727
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no H. pylori eradication treatment).
Study: 15172264
Drug: Preoperative intraaortic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative intraaortic balloon pump (IABP) therapy
Study: 9725756
Drug: Diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (15 mg oral)
Study: 9065553
Drug: IVIg (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (2 g/kg intravenous immunoglobulin)
Study: 1775594
Drug: d‐ala‐Peptide‐T‐amide (Peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐ala‐Peptide‐T‐amide (Peptide T) intravenous administration at doses ranging from 0.1 to 3.2 mg/kg/day for 12 weeks
Study: 1775594
Drug: Intranasal Peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Peptide T at 25 mg/day for 8 weeks after a 4-week off-drug period
Study: 1775594
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (no drug administration)
Study: 7046652
Drug: Rifamycin SV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifamycin SV, 500 mg weekly
Study: 7046652
Drug: Saline solution,
Normalized name: Sterile Saline Solution, Contact Lens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution, 10 ml
Study: 23301471
Drug: Acupoint embedding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint embedding therapy
Study: 26511489
Drug: Glucoraphanin (GFN)
Normalized name: Guaifenesin
DrugBank: Glucoraphanin (DB15436)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucoraphanin (GFN) supplement providing Sulforaphane (SFN)
Study: 1438647
Drug: Imipramine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (1 mg/kg)
Study: 4026972
Drug: Ethanol infusion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol infusion to reach blood alcohol concentration of 1 mg/ml in 1 hr
Study: 4026972
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (control)
Study: 18807574
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of dental implants (20 implants)
Study: 18807574
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of dental implants (20 implants)
Study: 10716066
Drug: Intranasal 17-beta-estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 17-beta-estradiol (300 microg)
Study: 10716066
Drug: Reservoir patch
Normalized name: RESERVOIR,CADD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reservoir patch (50 microg/day of 17-beta-estradiol)
Study: 10716066
Drug: Tablet (2
Normalized name: VOYDEYA Tablet (200mg Dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (2 mg micronised 17-beta-estradiol)
Study: 8538478
Drug: Menorest 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menorest 50 twice weekly for 12 weeks
Study: 8538478
Drug: Premarin 0.625
Normalized name: Premarin 0.625mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin 0.625 mg daily for 12 weeks
Study: 1985041
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment (psychotherapy, relaxation, and standard medical treatment)
Study: 26817916
Drug: Tumor differentiation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor differentiation, postoperative chemotherapy, and pre-MSH6 expression
Study: 24534207
Drug: αTMS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: αTMS treatment group
Study: 21392832
Drug: Bone Marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone Marrow Stem Cells (BMSC) intracoronary infusion
Study: 17567869
Drug: Rifaximin 400
Normalized name: Rifaximin 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 400 mg 3 times daily for 4 weeks
Study: 12745558
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg vitamin C twice daily until 34 weeks' gestation
Study: 16368577
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo twice daily until 34 weeks' gestation
Study: 12501129
Drug: NVP increased
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP increased from 400 mg/day to 600 mg/day
Study: 12501129
Drug: Standard NVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard NVP dosing (400 mg/day)
Study: 7814752
Drug: Beta 1‐adrenolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 1‐adrenolytic agent
Study: 7814752
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no adrenolytic agents)
Study: 7814752
Drug: Alpha 1‐adrenolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha 1‐adrenolytic agent
Study: 31894993
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) as an adjunct to pharmacotherapy
Study: 15777891
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral iron therapy of 100 mg of elemental iron
Study: 15777891
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of iron sorbitol intramuscularly, repeated at an interval of 4‐6 weeks
Study: 27918586
Drug: Multiple Micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Micronutrient (MM) supplements (15 micronutrients with similar amounts of IFA)
Study: 27918586
Drug: Iron-Folic Acid
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-Folic Acid (IFA) supplements (60 mg Fe and 2800 μg FA)
Study: 27918586
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2800 μg FA)
Study: 22192331
Drug: Der p-SIT
Normalized name: Diäthylaminoäthanol ester der p-butylaminobenzösäure
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Der p-SIT + pharmacotherapy
Study: 1778354
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment and/or increase of physical activity or training
Study: 6954092
Drug: Pressurized aerosol
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pressurized aerosol salbutamol (0.1-2.4 mg)
Study: 6954092
Drug: Powder aerosol
Normalized name: Aluminum Chlorohydrate 8.8 g in 100 g TOPICAL AEROSOL, SPRAY [SUAVE POWDER AEROSOL ANTIPERSPIRANT AND DEODORANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder aerosol salbutamol (0.2-4.8 mg)
Study: 28650331
Drug: Th17 cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Th17 cells and CD4+ CD25+ Foxp3+ cells after 6 months of chemotherapy
Study: 28650331
Drug: Serum IL‐17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum IL‐17 and TGF‐β levels after 6 months of chemotherapy
Study: 25738177
Drug: 5 mm
Normalized name: SUR-FIT 45 mm Wafer, Small
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mm implants
Study: 25738177
Drug: 11.5 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.5 mm implants
Study: 25738177
Drug: Long maxillary
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long maxillary implants
Study: 25738177
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of short vs long implants
Study: 17445287
Drug: Anticonvulsant withdrawal
Normalized name: ANTICONVULSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsant withdrawal
Study: 15910687
Drug: Heberitro (formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heberitro (formulation A)
Study: 15910687
Drug: Eprex (formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprex (formulation B)
Study: 15235998
Drug: 0.25% or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% or 0.5% bupivacaine at a rate of 3‐7 ml.hr(‐1)
Study: 15235998
Drug: 0.01% morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% morphine at a rate of 1‐2 ml.hr(‐1)
Study: 28358452
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg isobaric levobupivacaine
Study: 28358452
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg isobaric bupivacaine
Study: 21136268
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia (IA)
Study: 9535992
Drug: EM574 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EM574 5 mg
Study: 9535992
Drug: EM574 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: EM574 10 mg
Study: 9535992
Drug: EM574 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: EM574 20 mg
Study: 9535992
Drug: EM574 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: EM574 30 mg
Study: 3189965
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (MgSO4) 2 grams administered IV for 20 minutes (0.40 mmol/min)
Study: 3189965
Drug: Saline (control)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (control) administered IV for 20 minutes
Study: 15800308
Drug: Amifostine (AM)
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine (AM) 500 mg IV four times per week
Study: 17087311
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with folic acid, vitamin B12, and B6
Study: 17087311
Drug: Vitamin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin treatment for reduction of hyperhomocysteinemia
Study: 12544649
Drug: Glycerol hyperhydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol hyperhydration (1.0 g.kg(-1))
Study: 12544649
Drug: Glycerol rehydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol rehydration (0.5 g.kg(-1))
Study: 9709312
Drug: Oral airway/Bag-Valve-Mask
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral airway/Bag-Valve-Mask (OA/BVM) system
Study: 29776899
Drug: Group exercise
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group exercise intervention using videoconferencing and mobile apps (e.g., Nike+, Sworkit) for 8 weeks.